{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}],"title":"Week 96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"}]}],"title":"Week 144"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"}]}],"title":"Week 192"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"}]}],"title":"Week 264"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}],"title":"Week 312"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"}]}],"title":"Week 360"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Week 408"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}],"title":"Week 468"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"Week 528"}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"description":"TFR is defined as no confirmed loss of MR4 (molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","groups":[{"description":"TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \\> 0.01% IS. Loss of MMR does not require confirmation.","id":"OG000","title":"TFR Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set (FAS) included all patients who completed the consolidation phase successfully and entered the TFR phase.","reportingStatus":"POSTED","timeFrame":"first 96, 144, 192, 264 weeks, and within the end of years 6, 7, 8, 9 and 10 following nilotinib cessation.","title":"Percentage of Participants in TFR Within 96, 144, 192, 264 Weeks, and Within the End of Years 6, 7, 8, 9 and 10 Following Nilotinib Cessation","type":"SECONDARY","unitOfMeasure":"Participants"}